Trial Profile

A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subject with Schizophrenia

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 May 2021 Results of post-hoc analyses evaluating relationship of SF-12 as an outcome measure of HRQOL in patients with schizophrenia, presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
25 Sep 2020 According to an Janssen media release, the company has obtained approval of paliperidone palmitate (Zeprion TRI) Suspension Intramuscular long-acting injection with a 12-week interval in Japan for the treatment of schizophrenia .
15 Sep 2020 Results comparing safety risks in clinical trials of PP3M and PP1M, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com